Showing results (1011-1020 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|April 29, 2016
GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development StrategiesSarapee Hirankarn, Jeffrey S Barrett, Naji Alamuddin, et al.
Clinical Pharmacology in Drug Development|April 28, 2016
Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjectsDawei Xuan, Scott McBride, Philip Wastall, et al.
Clinical Pharmacology in Drug Development|April 28, 2016
Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjectsJoachim Tillner, Anne Lehmann, Tobias Paehler, et al.
Clinical Pharmacology in Drug Development|April 28, 2016
Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulationGirish Bende, Shibadas Biswal, Prafulla Bhad, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Systemic exposure to benzoic acid and hippuric acid following topical application of clindamycin 1%/benzoyl peroxide 3% fixed-dose combination gel in Japanese patients with acne vulgarisHiroko Ino, Naoki Takahashi, Alessandra Alio Saenz, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicinApexa Bernard, Nicole Vaccaro, Milin Acharya, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditionsXiang Gao, Marie-Noella Ndongo, Tina M Checchio, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteersSriram Krishnaswami, Mary Boy, Vincent Chow, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitusJulia Zack, Jolene Berg, Axel Juan, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levelsErik T Te Beek, Xia Chen, Gabriël E Jacobs, et al.
Pageof 136